Research analysts at Zacks Research cut their Q3 2027 EPS estimates for Haemonetics in a note issued to investors on Wednesday, January 29th. Zacks Research analyst R. Department now forecasts that ...
Hosted on MSN19h
Why Experts Are Investing In A Stock Down By More Than 50%Investing in a stock that is down significantly can actually be a good long-term plan, if the company is established and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback